Poxel SA

Poxel SAis a lyonbiopole member

General information

259/261 avenue Jean Jaurès

69007 Lyon

Incorporated in: 2009/03/11

Number of employees: 23

More information


Main activity

Poxel is a diabetes drug development specialist, aiming at finding innovative solutions for the management of metabolic diseases. Poxel's rich pipeline of first-in-class products with disease-modifying mechanisms of action offering potential for safer, more effective therapies. The lead compound, Imeglimin, a mitochondria bioenergetics regulator, acting on the two main defects of Type 2 diabetes i.e. increasing insulin secretion in a glucose-dependent manner and improving insulin sensitivity, has just completed its phase 2b clinical trial to treat Type 2 diabetes. It has achieved proof-of-concept in two monotherapy clinical trials and as add-on therapy to the standard treatments. In addition, Poxel's portfolio includes a direct AMPK activator nearing phase 1 clinical development. This compound did prove benefits in preclinical studies for the treatment of Type 2 diabetes and co-morbidities. Poxel was formed in 2009 as a spin out from Merck Serono, a leading global player in the field of metabolic disorders.


Looking for funding: Yes

Private funding obtained: €34m from Edmond de Rothschild Investment Partners,Bpi France and Omnes Capital (ex-Credit Agricole Private Equity)

Public funding obtained: Sept. 2009: €215,000 grant from FEDER and €250,000 grant from Le Grand Lyon for  NATHEB project. Oct. 2011: €1.45m from OSEO

Stock exchange listing: Listed on Euronext on February 6, 2015: €26;8 M raised

Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine

Application market

Therapeutics, Pharma or Biotech


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree